DYNC1LI2

Across TCGA pan-cancer cohorts, DYNC1LI2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DYNC1LI2 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DYNC1LI2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DYNC1LI2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

LUAD, GBM, and CCRCC are the cancer types where DYNC1LI2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.823	0.963	.003	13	view →
GBM	OS	Tertile	All	0.241	0.545	.025	3	view →
CCRCC	DFS	Median	IV	0.781	0.220	.017	3	view →
PDAC	OS	Quartile	III,IV	1.000	0.526	.040	1	view →
LSCC	DFS	Quartile	III,IV	0.568	1.000	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DYNC1LI2–LUAD (DFS)

Open the LUAD breakdown →